A key mechanism of tumor resistance to immune cells is mediated by the expression of peptide‐loaded HLA class I molecule (HLA‐E) in tumor cells, which suppresses NK cell activity via ligation of the NKG2A.166. This evidence concerns the gene KLRC1 and neoplasm.